Director/PDMR Shareholding

RNS Number : 4971W

Advanced Oncotherapy PLC

18 August 2020

 

18 August 2020

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director/PDMR Shareholding

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr. Michael Sinclair, Executive Chairman, has purchased a total of 145,000 ordinary shares of 25p each in the Company ("Ordinary Shares") at an average price of 32.18 pence per share.

Following these purchases, Dr Sinclair has a total beneficial interest in 8,280,604 Ordinary Shares, equivalent to 2.70 per cent. of the Company's issued share capital.   

Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited  (Nomad & Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales & Broking)	Tel: [phone]
FTI Consulting  (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

Notes for Editors

About Advanced Oncotherapy Plc  www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

1	Details of the person discharging managerial responsibilities
a)	Name	Michael Sinclair
2	Reason for the notification
a)	Position/status	Executive Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Advanced Oncotherapy plc
b)	LEI	213800LUDHZOG3YT6C82
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 25p each in  Advanced Oncotherapy plc Identification code (ISIN) for  Advanced Oncotherapy plc ordinary shares: GB00BD6SX109
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)	Date Volume Average price (pence) 17 August 2020 65,000 29.97 18 August 2020 80,000 33.97
d)	Aggregated information - Aggregated volume - Price	145,000 Ordinary Shares Average price of 32.18 pence per Ordinary Share
e)	Date of the transaction	See 4 c) above
f)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHBUGDIIDBDGGI